ADRB2
Beta-2 adrenergic receptor
As of the edition of 20 October 2026, ADRB2 (beta-2 adrenergic receptor, UniProt P07550) has 64 drugs tested at it and 78 companies on the list, 8 on route A and 11 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P07550
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 149
- Disease areas
- Lungs and airways; Immune system; Heart and blood vessels; Nervous system; Eye; Cancer; Infections; Urinary and reproductive
- Registered trials of its drugs
- 2,068
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 40 |
| Active | 1 |
| Went quiet | 17 |
| Stopped | 3 |
| Withdrawn from market | 2 |
| Status not established | 1 |
| Total | 64 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Epinephrine | Marketed | Phase 4 | none listed |
| Albuterol | Marketed | Phase 4 | none listed |
| Propranolol | Marketed | Phase 4 | none listed |
| Formoterol | Marketed | Phase 4 | none listed |
| Norepinephrine | Marketed | Phase 4 | none listed |
| Salmeterol | Marketed | Phase 4 | none listed |
| Carvedilol | Marketed | Phase 4 | none listed |
| Timolol | Marketed | Phase 4 | none listed |
| Indacaterol | Marketed | Phase 4 | none listed |
| Vilanterol | Marketed | Phase 4 | none listed |
| Olodaterol | Marketed | Phase 4 | Ends 2027 |
| Ephedrine | Marketed | Phase 4 | none listed |
12 of 64 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Route B | 11 |
| Engaged | 18 |
| Undetermined | 41 |
| Total on the list | 78 |
The other 75 companies at ADRB2
In the product78 companies in all; 75 are not named here, and no score is.
See the 78 companies at ADRB2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.